ATE535514T1 - Carboxamid-spirohydantoin-cgrp-rezeptor- antagonisten - Google Patents
Carboxamid-spirohydantoin-cgrp-rezeptor- antagonistenInfo
- Publication number
- ATE535514T1 ATE535514T1 AT04719234T AT04719234T ATE535514T1 AT E535514 T1 ATE535514 T1 AT E535514T1 AT 04719234 T AT04719234 T AT 04719234T AT 04719234 T AT04719234 T AT 04719234T AT E535514 T1 ATE535514 T1 AT E535514T1
- Authority
- AT
- Austria
- Prior art keywords
- receptor antagonists
- cgrp receptor
- carboxamide
- compounds
- spirohydantoin cgrp
- Prior art date
Links
- 108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 title abstract 2
- QAHZIGHCEBUNGT-QMGFNSACSA-N (5r,6s,7s,8r,9r)-6,7,8-trihydroxy-9-(hydroxymethyl)-1,3-diazaspiro[4.5]decane-2,4-dione Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)C[C@]11C(=O)NC(=O)N1 QAHZIGHCEBUNGT-QMGFNSACSA-N 0.000 title 1
- 102000008323 calcitonin gene-related peptide receptor activity proteins Human genes 0.000 title 1
- 150000003857 carboxamides Chemical class 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 abstract 2
- 102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 abstract 2
- 102000014468 Calcitonin Gene-Related Peptide Receptors Human genes 0.000 abstract 1
- 208000006561 Cluster Headache Diseases 0.000 abstract 1
- 206010019233 Headaches Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 208000018912 cluster headache syndrome Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 231100000869 headache Toxicity 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
- C07D233/78—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45560803P | 2003-03-14 | 2003-03-14 | |
| PCT/US2004/007226 WO2004082602A2 (en) | 2003-03-14 | 2004-03-10 | Carboxamide spirohydantoin cgrp receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE535514T1 true ATE535514T1 (de) | 2011-12-15 |
Family
ID=33030029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04719234T ATE535514T1 (de) | 2003-03-14 | 2004-03-10 | Carboxamid-spirohydantoin-cgrp-rezeptor- antagonisten |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7288559B2 (de) |
| EP (1) | EP1613368B1 (de) |
| JP (1) | JP4690313B2 (de) |
| AT (1) | ATE535514T1 (de) |
| AU (1) | AU2004222378B2 (de) |
| CA (1) | CA2518830A1 (de) |
| WO (1) | WO2004082602A2 (de) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7220862B2 (en) | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
| US7842808B2 (en) | 2002-06-05 | 2010-11-30 | Bristol-Myers Squibb Company | Anti-migraine spirocycles |
| EP1606286B1 (de) * | 2003-03-14 | 2011-05-11 | Merck Sharp & Dohme Corp. | Benzodiazepinspirohydantoine als cgrp-rezeptorantagonisten |
| TW200524601A (en) | 2003-12-05 | 2005-08-01 | Bristol Myers Squibb Co | Heterocyclic anti-migraine agents |
| TW200533398A (en) | 2004-03-29 | 2005-10-16 | Bristol Myers Squibb Co | Novel therapeutic agents for the treatment of migraine |
| JP2008512460A (ja) * | 2004-09-08 | 2008-04-24 | メルク エンド カムパニー インコーポレーテッド | 単環式アニリドスピロラクタムｃｇｒｐ受容体拮抗薬 |
| US7390798B2 (en) | 2004-09-13 | 2008-06-24 | Merck & Co., Inc. | Carboxamide spirolactam CGRP receptor antagonists |
| US7384930B2 (en) | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
| US7384931B2 (en) | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
| US7449586B2 (en) | 2004-12-03 | 2008-11-11 | Bristol-Myers Squibb Company | Processes for the preparation of CGRP-receptor antagonists and intermediates thereof |
| US7834007B2 (en) | 2005-08-25 | 2010-11-16 | Bristol-Myers Squibb Company | CGRP antagonists |
| US8168592B2 (en) | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
| SI3045182T1 (en) * | 2005-11-14 | 2018-08-31 | Teva Pharmaceuticals International Gmbh | An antibody to a peptide-associated peptide antagonist to calcitonin for treating a headache in aggregates |
| EP1954135B1 (de) * | 2005-11-18 | 2012-10-10 | Merck Sharp & Dohme Corp. | Spirolactam-aryl cgrp-rezeptor-antagonisten |
| CA2629406A1 (en) | 2005-11-18 | 2007-05-31 | Merck & Co., Inc. | Spirohydantoin aryl cgrp receptor antagonists |
| EP2013213B1 (de) | 2006-05-02 | 2011-07-27 | Bristol-Myers Squibb Company | Verbindungen mit eingeschränkter konformation als cgrp rezeptor antagonisten. |
| US7470680B2 (en) | 2006-05-03 | 2008-12-30 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
| JP5511379B2 (ja) * | 2006-07-21 | 2014-06-04 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｃｇｒｐレセプターアンタゴニスト |
| US7951795B2 (en) * | 2006-12-08 | 2011-05-31 | Merck Sharp & Dohme Corp. | Constrained spirocyclic compounds as CGRP receptor antagonists |
| KR101304150B1 (ko) | 2008-03-04 | 2013-09-05 | 라브리스 바이올로직스 인코포레이티드 | 만성 통증의 치료 방법 |
| EP2356106A1 (de) | 2008-10-07 | 2011-08-17 | Schering Corporation | Biarylspiroaminooxazolinanaloga als modu modulatoren des alpha2c-adrenergen rezeptors |
| WO2010042475A1 (en) * | 2008-10-07 | 2010-04-15 | Schering Corporation | Spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators |
| BR112012004464B8 (pt) | 2009-08-28 | 2021-05-25 | Labrys Biologics Inc | uso de um anticorpo antagonista anti-cgrp para preparar uma composição farmacêutica para tratar e/ou prevenir dor visceral e/ou um ou mais sintomas de dor visceral, em que a dor visceral está associada á cistite intersticial (ic), e dita composição farmacêutica |
| TWI501968B (zh) | 2010-11-12 | 2015-10-01 | Merck Sharp & Dohme | 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑 |
| WO2012064911A1 (en) * | 2010-11-12 | 2012-05-18 | Merck Sharp & Dohme Corp. | Piperidinone carboxamide indane cgrp receptor antagonists |
| WO2012129013A1 (en) * | 2011-03-18 | 2012-09-27 | Merck Sharp & Dohme Corp. | Piperidinone carboxamide spirohydantoin cgrp receptor antagonists |
| CN108014334B (zh) | 2011-05-20 | 2021-11-30 | H.伦德贝克公司 | 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途 |
| PT3495392T (pt) | 2011-05-20 | 2021-09-22 | H Lundbeck As | Composições anti-cgrp e a sua utilização |
| EA033109B1 (ru) | 2011-05-20 | 2019-08-30 | Олдербайо Холдингз Ллк | Способы ингибирования, профилактики или лечения диареи и/или поддержания соответствующих уровней электролитов и жидкости в толстой кишке субъекта, подвергающегося связанному с диареей состоянию, с помощью антитела против cgrp или фрагмента антитела против cgrp |
| WO2013169565A1 (en) * | 2012-05-09 | 2013-11-14 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
| EP2846799B1 (de) | 2012-05-09 | 2017-11-15 | Merck Sharp & Dohme Corp. | Spirolactam-cgrp-rezeptorantagonisten |
| US20170114122A1 (en) | 2015-10-23 | 2017-04-27 | Alderbio Holdings Llc | Regulation of glucose metabolism using anti-cgrp antibodies |
| US12168004B2 (en) | 2014-02-05 | 2024-12-17 | Merck Sharp & Dohme Llc | Treatment of migraine |
| US10117836B2 (en) | 2014-02-05 | 2018-11-06 | Merck Sharp & Dohme Corp. | Tablet formulation for CGRP active compounds |
| US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| MX378344B (es) | 2014-03-21 | 2025-03-10 | Teva Pharmaceuticals Int Gmbh | Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos. |
| FR3030521B1 (fr) * | 2014-12-23 | 2019-07-26 | Galderma Research & Development | Nouveaux composes heterocycliques et leur utilisation en medecine ainsi qu'en cosmetique |
| US9815850B2 (en) | 2016-02-05 | 2017-11-14 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| SMT202600087T1 (it) | 2016-09-23 | 2026-03-09 | Teva Pharmaceuticals Int Gmbh | Trattamento dell’emicrania refrattaria |
| LT3552017T (lt) | 2016-12-09 | 2022-05-10 | Denali Therapeutics Inc. | Junginiai, naudotini kaip ripk1 inhibitoriai |
| EP3366286A1 (de) | 2017-02-22 | 2018-08-29 | Johannes Keller | Verbindungen zur behandlung von sepsis |
| WO2018187667A1 (en) * | 2017-04-06 | 2018-10-11 | Alliance For Sustainable Energy, Llc | Renewable polymers and resins and methods of making the same |
| US12383545B1 (en) | 2018-06-08 | 2025-08-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| CR20210373A (es) | 2019-01-08 | 2021-08-19 | H Lundbeck As | Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp |
| GEAP202515803A (en) | 2019-05-02 | 2025-06-10 | H Lundbeck As | Treatment of headache using anti-cgrp antibodies |
| KR20210124867A (ko) | 2020-04-06 | 2021-10-15 | 하. 룬드벡 아크티에셀스카브 | 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료 |
| MX2023001071A (es) | 2020-07-29 | 2023-05-12 | Allergan Pharmaceuticals Int Ltd | Tratamiento de la migraña. |
| CA3206184A1 (en) | 2020-12-22 | 2022-06-30 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| JP2024533756A (ja) | 2021-09-27 | 2024-09-12 | アラガン ファーマスーティカルズ インターナショナル リミテッド | アトゲパントを含む片頭痛の併用療法 |
| EP4463229A1 (de) | 2022-01-12 | 2024-11-20 | Denali Therapeutics Inc. | Kristalline formen von (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b! [l,4)oxazepin-3-yl)-4h-1,2,4-triazol-3-carboxamid |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4772632A (en) * | 1987-02-24 | 1988-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | Antineoplastic, system - L specific amino acid nitrogen mustards |
| FR2709306B1 (fr) * | 1993-07-20 | 1995-10-20 | Adir | Nouveaux dérivés de benzospiroalcène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
| AUPN449295A0 (en) * | 1995-07-28 | 1995-08-24 | Inner And Eastern Health Care Network, The | Radioprotectors |
| JP3449084B2 (ja) * | 1995-12-25 | 2003-09-22 | 富士レビオ株式会社 | ヒダントイン誘導体 |
-
2004
- 2004-03-10 US US10/546,889 patent/US7288559B2/en not_active Expired - Lifetime
- 2004-03-10 AU AU2004222378A patent/AU2004222378B2/en not_active Ceased
- 2004-03-10 EP EP04719234A patent/EP1613368B1/de not_active Expired - Lifetime
- 2004-03-10 CA CA002518830A patent/CA2518830A1/en not_active Abandoned
- 2004-03-10 JP JP2006507015A patent/JP4690313B2/ja not_active Expired - Fee Related
- 2004-03-10 WO PCT/US2004/007226 patent/WO2004082602A2/en not_active Ceased
- 2004-03-10 AT AT04719234T patent/ATE535514T1/de active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006520381A (ja) | 2006-09-07 |
| AU2004222378A1 (en) | 2004-09-30 |
| EP1613368B1 (de) | 2011-11-30 |
| CA2518830A1 (en) | 2004-09-30 |
| EP1613368A4 (de) | 2008-06-18 |
| AU2004222378B2 (en) | 2008-08-14 |
| WO2004082602A2 (en) | 2004-09-30 |
| EP1613368A2 (de) | 2006-01-11 |
| US7288559B2 (en) | 2007-10-30 |
| US20070111982A1 (en) | 2007-05-17 |
| WO2004082602A3 (en) | 2005-11-17 |
| JP4690313B2 (ja) | 2011-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE516803T1 (de) | Aryl-spirohydantoin-cgrp-rezeptor-antagonisten | |
| EP1606286A4 (de) | Benzodiazepinspirohydantoine als cgrp-rezeptorantagonisten | |
| ATE394400T1 (de) | Bicyclische anilidspirohydantoine als cgrp- rezeptorantagonisten | |
| ATE556060T1 (de) | Monocyclische anilidspirohydantoine als cgrp- rezeptorantagonisten | |
| WO2004082602A3 (en) | Carboxamide spirohydantoin cgrp receptor antagonists | |
| JO2355B1 (en) | Hereditary calcitonin polypeptide receptor antagonists | |
| DE602005020655D1 (de) | Carboxamid-spirolactam-cgrp-rezeptor-antagonisten | |
| NO20072435L (no) | CGRP-reseptorantagonister | |
| ATE464305T1 (de) | Bicyclische anilidspirolactame als antagonisten des cgrp-rezeptors | |
| ATE466860T1 (de) | Cgrp-rezeptorantagonisten | |
| WO2005000807A3 (en) | Benzodiazepine cgrp receptor antagonists | |
| WO2005013894A3 (en) | Benzodiazepine cgrp receptor antagonists | |
| ATE537170T1 (de) | Cgrp-rezeptorantagonisten | |
| DE602007008434D1 (de) | Rezeptoren | |
| EP1794133A4 (de) | Arylspirolactamverbindungen als antagonisten des cgrp-rezeptors | |
| ATE463245T1 (de) | Tricyclische anilid-spirohydantoin-cgrp- rezeptorantagonisten | |
| DE602006019304D1 (de) | Spirohydantoin-aryl-cgrp-rezeptorantagonisten | |
| EP1794146A4 (de) | Tricyclische anilid-spirohydantoin-cgrp-rezeptorantagonisten | |
| ATE503755T1 (de) | Cgrp-rezeptorantagonisten | |
| ATE507880T1 (de) | Cgrp-rezeptorantagonisten | |
| ATE466853T1 (de) | Cgrp-rezeptorantagonisten |